



OPEN ACCESS

EDITED AND REVIEWED BY

Ichiro Manabe,
Chiba University, Japan

*CORRESPONDENCE

Yasutaka Takeda
✉ yktake5@asahikawa-med.ac.jp

SPECIALTY SECTION

This article was submitted to Cardiovascular Metabolism, a section of the journal Frontiers in Cardiovascular Medicine

RECEIVED 23 February 2023

ACCEPTED 02 March 2023

PUBLISHED 16 March 2023

CITATION

Takeda Y, Sakuma I, Hiramitsu S, Okada M, Ueda S and Sakurai M (2023) Corrigendum: The effects of pemafibrate and Omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study).
Front. Cardiovasc. Med. 10:1172664.
doi: 10.3389/fcvm.2023.1172664

COPYRIGHT

© 2023 Takeda, Sakuma, Hiramitsu, Okada, Ueda and Sakurai. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: The effects of pemafibrate and Omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)

Yasutaka Takeda^{1*}, Ichiro Sakuma², Shinya Hiramitsu³, Mizuho Okada⁴, Shinichiro Ueda⁵ and Masaru Sakurai⁶

¹Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan, ²Caress Sapporo Hokko Memorial Clinic, Sapporo, Japan, ³Hiramitsu Heart Clinic, Nagoya, Japan, ⁴Keiyukai Yoshida Hospital, Asahikawa, Japan, ⁵Department of Clinical Pharmacology and Therapeutics, University of the Ryukyus, Nishihara, Japan, ⁶Department of Social and Environmental Medicine, Kanazawa Medical University, Uchinada, Japan

KEYWORDS

apolipoprotein B-48, atherosclerotic cardiovascular disease, residual risk, hypertriglyceridemia, pemafibrate, polyunsaturated fatty acids

A Corrigendum on

The effects of pemafibrate and Omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)

By Takeda Y, Sakuma I, Hiramitsu S, Okada M, Ueda S and Sakurai M. (2023) Front. Cardiovasc. Med. 10:1094100. doi: 10.3389/fcvm.2023.1094100

In the published article, there was an error in **Table 6** (Adverse events) as published. The error was found in the percentage of participants with sepsis associated with enteritis in the PEMA group. The corrected table appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

TABLE 6 Adverse events.

	PEMA (<i>n</i> = 63)	OMEGA-3 (<i>n</i> = 63)
AEs	9 (14.3)	3 (4.8)
Participants who discontinued treatment because of drug-related AE		
Nausea	1 (1.6)	0 (0.0)
Pain in the extremities	1 (1.6)	0 (0.0)
Erythema on the forearm	1 (1.6)	0 (0.0)
Itching in the forearm	1 (1.6)	0 (0.0)
General malaise	1 (1.6)	0 (0.0)
Anorexia	1 (1.6)	0 (0.0)
Participants who discontinued treatment because of drug-unrelated AE		
Neck stiffness	1 (1.6)	0 (0.0)
Tooth pain	1 (1.6)	0 (0.0)
Sepsis associated with enteritis	1 (1.6)	0 (0.0)
Other AEs		
Worsening of glycemic control	2 (3.2)	1 (1.6)
Acute epiglottitis	1 (1.6)	0 (0.0)
Dental caries	1 (1.6)	0 (0.0)
Liver dysfunction	1 (1.6)	0 (0.0)
Muscular pain	1 (1.6)	0 (0.0)
Fall	0 (0.0)	1 (1.6)
Lumbago	0 (0.0)	1 (1.6)
Elevation of serum CK	0 (0.0)	1 (1.6)